Johnson & Johnson
This article was originally published in The Tan Sheet
McNeil Consumer fourth quarter worldwide growth of 19% was "primarily the result" of the buyout of Merck's equity stake in the European nonprescription pharmaceutical business, J&J reports. Inspired by strong performance from Splenda, McNeil is "continuing to look at models and new opportunities to broaden that whole nutritional area, so we've got a whole organization looking at it" reports J&J CEO William Weldon. "We do feel there's a big opportunity, especially with the needs of childhood obesity and other things that are out there today." J&J global fourth quarter sales increased 13.3% to $12.8 bil...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”